Flu vaccine market is set to reach US$ 10.74 billion by 2033, North America leads the market with 48% market share.

The global flu vaccine market reached US$ 5.70 billion in 2024 and is expected to reach US$ 10.74 billion by 2033, growing at a CAGR of 7.3% during the forecast period 2025-2033.

DataM Intelligence unveils its latest report on the "flu vaccine Market size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts, and emerging opportunities that can guide businesses in seizing growth potential and crafting winning strategies. Packed with data-driven insights on current developments and future trends, this report is essential for companies aiming to stay ahead in the competitive Market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/flu-vaccine-market?prtk

United States: Key Industry Developments (2025):-
✅ October 2025: Sanofi launched a new high‐dose quadrivalent influenza vaccine tailored for elderly populations, aiming to boost protection in high‐risk groups and support demand ahead of the 2025‐26 flu season.

✅ October 2025: The CDC recommended universal influenza vaccination for everyone aged 6 months and older, broadening the target population and potentially increasing seasonal flu vaccine uptake across the U.S.

✅ October 2025: Seqirus opened a state‐of‐the‐art facility in the U.S. to expand cell‐based flu vaccine manufacturing capacity, strengthening domestic supply resilience for future seasons.

✅ July 2025: GSK began shipping trivalent seasonal influenza vaccine doses (FLULAVAL and FLUARIX) across the U.S. for the upcoming 2025‐26 flu season after FDA lot‐release approval, ensuring wider immunization availability.

✅ March 2025: Sanofi adopted the FDA‐selected influenza strains into its 2025‐26 vaccine production portfolio (including FLUZONE High‐Dose and FLUBLOK), aligning manufacturing with regulatory recommendations.

Japan: Key Industry Developments (2025):-
✅ November 2025: A panel from Japan's Ministry of Health formally endorsed adding Sanofi's high‐dose influenza vaccine (Efluelda) to the national immunization program for older adults (75+), broadening coverage for vulnerable populations.

✅ Late 2025: Japan's health authorities approved new influenza vaccine products amid a seasonal decline in flu cases, marking expanded vaccine availability and updated market offerings.

✅ 2025 (general): Ongoing initiatives support advancement of flu vaccine technologies, including discussion on nasal spray vaccine approval and broader immunization strategies to strengthen seasonal prevention efforts.

📌 flu vaccine Market 2025-26 M&A Deals:-
→ In December 2025, Sanofi agreed to acquire Dynavax Technologies in an all‐cash deal valued at approximately $2.2 billion. The transaction broadens Sanofi's vaccine portfolio which already includes influenza vaccines by adding Dynavax's marketed adult products (including HEPLISAV‐B) and pipeline assets. The acquisition is expected to close in early 2026.

→ In November 2025, Merck & Co. agreed to buy Cidara Therapeutics for about $9.2 billion (roughly $221.50 per share in cash). While Cidara's lead asset is an influenza antiviral candidate rather than a traditional vaccine, the deal significantly expands Merck's infectious disease and flu‐focused pipeline and is expected to close by Q1 2026.

→ In July 2025, Sanofi acquired UK biotech Vicebio Ltd. in a deal valued at up to $1.6 billion including $1.15 billion upfront with additional contingent milestone payments. Vicebio's respiratory vaccine technology complements Sanofi's existing vaccines (e.g., flu) and strengthens its respiratory portfolio.

flu vaccine Market Drivers:-
◾ Many governments purchase and distribute vaccines via national programs driving stable, predictable demand. For example, the U.S. CDC procured vaccines to support around 174 M Americans in one season (~2023-24).

◾ Similar programs in EU nations saw a ~15% increase in vaccine doses procured year‐on‐year.

◾ National mandates now exist in ~62% of countries worldwide, elevating adult immunization uptake.

◾ Improved health awareness campaigns, leading to higher preventive care adoption. Hospital‐based immunization programs now report coverage exceeding 78%.

◾ Workplace vaccination initiatives reduce absenteeism ~36% of adults now access flu shots through employers.

◾ Seasonal flu causes millions of severe cases annually (3-5 M), reinforcing the need for vaccination.

◾ The geriatric population particularly those 65+ is rising rapidly, increasing need for targeted influenza protection.

◾ Aging populations correlate with higher severe flu risks, prompting public health policies that emphasize annual vaccination.

📌 Buy Now & Unlock 360° Market Intelligence:https://www.datamintelligence.com/buy-now-page?report=flu-vaccine-market?prtk

🚆 Key Players:-

AstraZeneca, GlaxoSmithKline PLC, Sanofi, Abbott Laboratories, Seqirus, Mitsubishi Tanabe Pharma, Serum Institute of India Pvt. Ltd, Mylan NV, GDK Biotechnology, Hualan Biological Engineering Inc., Adimmune Corporation, Sinovac Biotech, and Changchun Institute of Biological Products, among others.

Top 5 Players - flu vaccine Market

1. Sanofi

Market Share: 24% of the global flu vaccine market.
About: French multinational with the leading influenza vaccine portfolio including Fluzone and Vaxigrip, widely distributed across 100+ countries.

2. GlaxoSmithKline (GSK)

Market Share: 22% globally (often cited around ~20%).
About: UK‐based pharma with strong flu vaccine products like Fluarix and FluLaval, supported by broad manufacturing capacity worldwide.

3. Seqirus (CSL Limited)

Market Share: 23% of the flu vaccine market.
About: Australia‐based subsidiary of CSL, leading in cell‐based influenza vaccines such as Flucelvax and Fluad.

4. AstraZeneca

Market Share: 6% (smaller than top three but significant).
About: UK pharma offers the FluMist intranasal vaccine and maintains global flu vaccine presence, particularly in niche segments.

5. Serum Institute of India Pvt. Ltd

Market Share: Smaller regional share (often 5% globally).
About: Major vaccine manufacturer in India with expanding influenza vaccine production and distribution in emerging markets.

flu vaccine Market Regional Highlights
North America
North America holds the largest share of the global flu vaccine market (48% of global revenue / demand), led by the U.S. and Canada due to advanced healthcare systems and widespread immunization programs.

High vaccination coverage, robust public health campaigns, and strong government support drive continuous market expansion.

Ongoing technological upgrades (e.g., cell‐based and recombinant vaccines) and year‐round production capacity strengthen regional growth.

Europe
Europe accounts for roughly 29% of the global flu vaccine market, supported by national vaccination policies and high coverage rates among adults and the elderly.

Comprehensive healthcare systems and strong public funding contribute to stable demand and consistent market development.

Regional focus on quadrivalent vaccines and coordinated immunization programs drives sustained uptake.

Asia‐Pacific
The Asia‐Pacific region contributes approximately 24% of the global flu vaccine market and is often noted as the fastest‐growing due to rising healthcare access and population size.

Expansion of immunization initiatives in countries like China, India, and Japan increases vaccination penetration.

Large population base and improving healthcare infrastructure support accelerating market adoption.

Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/flu-vaccine-market?prtk

flu vaccine segmentation :
The Flu Vaccine Market is segmented by type, which includes whole virus vaccines, split virus vaccines, subunit vaccines, and live attenuated virus vaccines, each designed to offer targeted protection against influenza strains. In terms of distribution channels, vaccines reach end-users through institutional setups, hospitals, community clinics, public health agencies, workplaces, retail outlets, retail pharmacies, and mail-order pharmacies, ensuring broad accessibility. The market is also segmented by application, focusing on vaccination for children below 3 years and for adults and children over 3 years, catering to the specific immunization needs of different age groups.

FAQ'S

Q: What is the current size of the Flu Vaccine Market?
A: The Flu Vaccine Market was valued at approximately USD 5.70 billion in 2024, with steady growth expected over the next decade.

Q: Which factors are driving growth in the Flu Vaccine Market?
A: Rising influenza prevalence, government vaccination programs, and technological advances in vaccine development are key growth drivers.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.